Drug intelligence / Profile preview

Epione 369

Development stage
Unknown
Lead developer
Epione Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Epione 369 is a nutraceutical dietary supplement developed by Epione Pharmaceuticals, formulated as a balanced blend of Omega-3, Omega-6, and Omega-9 fatty acids. Typically derived from botanical sources such as flaxseed oil, these fatty acids serve as essential structural components of cellular membranes and act as precursors to bioactive lipid mediators like eicosanoids. Omega-3 and Omega-6 are essential fatty acids that must be obtained through diet, while Omega-9 is a non-essential fatty acid that supports metabolic health. The supplement is intended to promote general wellness, specifically targeting cardiovascular health, cognitive function, and the maintenance of healthy skin and joints by modulating inflammatory pathways and supporting lipid metabolism.

Brand names
Epione 369Epione369Epione-369
Other names
Epione 3-6-9Epione3-6-9Epione-3-6-9
02

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)FFAR4 (Free fatty acid receptor 4)

Beyond the preview

Go deeper on Epione 369.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epione 369.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call